GEHCV GE HEALTHCARE TECHNOLOGIES INC

GE HealthCare names new president and CEO, China

GE HealthCare (Nasdaq: GEHC), a leading global healthcare solutions provider, today announced that Yihao Zhang, president and CEO, China, will retire from the company effective July 1, 2025. Will Song, a Johnson & Johnson veteran for over 20 years, has been named GE HealthCare’s new president and CEO, China, and will join the company on April 1, 2025, ahead of leading the region starting July 1 following Yihao’s departure.

Yihao’s planned retirement allowed GE HealthCare to purposefully identify and prepare a qualified successor in Will, an exceptional leader with a strong track-record and the right skillsets to help deliver the company’s local strategy.

Since joining GE HealthCare in 2019, Yihao has been responsible for GE HealthCare’s strategic development and operations in China, driving the company’s long-term growth in the market. He has redefined the company’s localization, innovation and partnership strategy in China, establishing a clear blueprint for long-term growth in the region. His efforts in developing and promoting industry-leading localization have been critical in transforming the industry and helping the company navigate in the highly evolving, policy-driven and competitive market. He also doubled innovation investment within five years and expanded the company’s manufacturing footprint in Beijing, Wuxi, Tianjin and Shanghai and built two new manufacturing sites in Chengdu and Shenzhen.

“Yihao has proven himself to be a humble, energetic, people-focused leader who embraced our company culture, strategy and purpose. He has made an indelible mark on our colleagues and the industry,” said Peter Arduini, president and CEO, GE HealthCare. “I want to personally thank Yihao for his leadership and contributions through the years, and for positioning GE HealthCare as a leading innovator in China. I wish him a healthy and happy retirement. Looking ahead, I am confident that Will’s stellar reputation and in-depth knowledge of the China market, along with his robust relationships with key stakeholders and deep understanding of our customer base, will help enhance our position in China and move the region forward to effectively deliver on the future of healthcare.”

Will joins GE HealthCare from Johnson & Johnson, where he served as global senior vice president and China chairman. He led the China Presidents’ Council to advance Johnson & Johnson’s journey of innovation in China across MedTech and Innovative Medicine businesses. He joined Johnson & Johnson in 2003 and held various global positions with increasing responsibilities.

Well respected in the China market, over the past decade, Will has served as vice chairman of the China Association of Medical Devices Industry, vice president of the China Association of Enterprises with Foreign Investment, and vice chairman, Shanghai Enterprises Directors Association. He has been recognized with multiple external honors for his accomplishments, impact on the healthcare industry and broader economic development. He holds a bachelor’s degree from Peking University, an MBA from the Wharton School of the University of Pennsylvania, and a Ph.D. in Molecular Biology and Biochemistry from the University of Massachusetts.

Will is going to be based in Shanghai, China. Yihao and Will are working closely over the next several months to get immersed in the business, which is strategically important to the company’s growth strategy, and enable a deliberate and effective transition period.

About GE HealthCare Technologies Inc.

GE HealthCare is a trusted partner and leading global healthcare solutions provider, innovating medical technology, pharmaceutical diagnostics, and integrated, cloud-first AI-enabled solutions, services and data analytics. We aim to make hospitals and health systems more efficient, clinicians more effective, therapies more precise, and patients healthier and happier. Serving patients and providers for more than 125 years, GE HealthCare is advancing personalized, connected and compassionate care, while simplifying the patient’s journey across care pathways. Together, our Imaging, Advanced Visualization Solutions, Patient Care Solutions and Pharmaceutical Diagnostics businesses help improve patient care from screening and diagnosis to therapy and monitoring. We are a $19.7 billion business with approximately 53,000 colleagues working to create a world where healthcare has no limits.

GE HealthCare is proud to be among .

Follow us on, , , , and for the latest news, or visit our website for more information.

EN
27/02/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on GE HEALTHCARE TECHNOLOGIES INC

Moody's Ratings assigns Baa2 rating to GE Healthcare's sr. notes; stab...

Moody's Ratings (Moody's) assigned a Baa2 rating to GE HealthCare Technologies Inc.'s ("GE HealthCare") proposed offering of senior unsecured notes. There are no changes to GE HealthCare's existing ratings including the Baa2 issuer rating, Baa2 senior unsecured notes ratings and (P)Baa2 senior unsec...

 PRESS RELEASE

GE HealthCare launches AI-driven, patient-friendly Invenia ABUS Premiu...

CHICAGO--(BUSINESS WIRE)-- GE HealthCare (Nasdaq: GEHC) announced the launch of Invenia™ Automated Breast Ultrasound (ABUS) Premium, the latest 3D ultrasound offering advanced artificial intelligence (AI) and innovative features to drive faster*, reproducible supplemental screening and streamline exam readings on patients with dense breasts. Approximately 71% of cancers occur in dense breasts.1 According to studies across the U.S. and Europe, 40% of women2 and 70% of Asian women3 have dense breast tissue, making them four to six times more likely to receive a breast cancer diagnosis.4 Early d...

 PRESS RELEASE

GE HealthCare and NVIDIA reimagine diagnostic imaging with autonomous ...

SAN JOSE, Calif.--(BUSINESS WIRE)-- GE HealthCare (Nasdaq: GEHC) today announced a collaboration with NVIDIA at GTC 2025, expanding the existing relationship between the two companies to focus on pioneering innovation in autonomous imaging, beginning with autonomous X-ray technologies and autonomous applications within ultrasound. GE HealthCare has been at the forefront of medical technology innovation with a series of “firsts” that date back more than a century, starting with the invention of its X-ray tube, followed by several others including the first handheld ultrasound, first 3D obstetr...

 PRESS RELEASE

GE HealthCare expands invasive cardiology solutions portfolio with Alt...

CHICAGO--(BUSINESS WIRE)-- GE HealthCare (Nasdaq: GEHC) today announced the launch of the AltiX AI.i edition of Mac-Lab™, CardioLab™ and ComboLab™. The AltiX AI.i editions are designed to improve the user experience, elevating workflow in the cardiac catheterization (cath) lab and supporting even the most complex electrophysiology (EP) procedures. These latest editions offer new features that can streamline workflow and enhance interoperability, while upholding strong cybersecurity standards. Cardiovascular disease (CVD) has nearly doubled over the past three decades, affecting more than 500 ...

 PRESS RELEASE

GE HealthCare Advances Its Cloud Strategy by Unveiling the Genesis Por...

LAS VEGAS--(BUSINESS WIRE)-- GE HealthCare (Nasdaq: GEHC) today announced its new Genesis solutions, a portfolio of cloud enterprise imaging software-as-a-service (SaaS) solutions. Four features will be offered when commercially released – edge, storage, vendor neutral archive and data migration.i These cloud solutions, are designed to help enhance healthcare organizations’ efficiency and precision, streamline workflows, and optimize the use of capital and IT resources. The growing volume and complexity of patient cases are putting increasing pressure on hospitals’ IT systems, driving the ne...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch